Fidaxomicin First in IBD-Associated C. difficile? A Clinician’s Guide to the 2026 AGA Update
A clinician-focused review of the 2026 AGA update on C. difficile infection in IBD, including fidaxomicin, diagnostic testing, immunosuppression, recurrence, and remaining evidence gaps.
When the familiar IBD flare is not quite what it seems
Most gastroenterologists have seen some version of this patient.
Someone with ulcerative colitis or Crohn’s colitis who had been reasonably stable returns with more diarrhea, worsening urgency, abdominal discomfort, and inflammatory markers heading in the wrong direction. The clinical picture looks familiar enough that escalation of IBD therapy naturally comes to mind.
But Clostridioides difficile infection complicates that reflex.
In patients with IBD, CDI and active intestinal inflammation can look remarkably similar. Missing an infection may delay appropriate antimicrobial treatment. At the other extreme, attributing everything to CDI because a molecular assay is positive can distract from active IBD that still needs treatment.
That uneasy overlap between infection and inflammation sits at the heart of the 2026 American Gastroenterological Association Clinical Practice Update, “AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review.”
The review, authored by Sahil Khanna, Jessica R. Allegretti, Jana G. Hashash, and Paul Feuerstadt, was published online on May 15, 2026, in Gastroenterology and appears in Volume 171, Issue 1, pages 184–192.
Before considering its recommendations, one point deserves emphasis. This is an AGA Clinical Practice Update Expert Review, not a randomized trial and not a formal systematic review generating graded evidence for every recommendation. It brings together published studies, existing guidelines, systematic reviews, and expert interpretation to provide practical advice for a difficult clinical problem.
That distinction does not diminish its usefulness. It simply tells us how confidently to hold the conclusions.
CDI in IBD is more than another cause of diarrhea
The higher burden of CDI in IBD has been recognized for some time, but the clinical consequences are worth keeping in view.
The AGA summary emphasizes prompt evaluation for CDI in patients with IBD involving the colon and reports an approximately eightfold higher risk than in the general population. Patients with IBD also experience more severe illness and more frequent recurrence than those without IBD.
The consequences may extend well beyond additional bowel movements. CDI in IBD has been associated with hospitalization, disease flares, escalation or failure of medical therapy, and a greater likelihood of surgery.
Association, however, is not the same thing as causation.
Patients who develop CDI may already have more severe inflammatory disease, greater healthcare exposure, recent antibiotic use, immunosuppression, or other characteristics that contribute to worse outcomes. It would therefore be overly simplistic to attribute every subsequent deterioration to the infection itself.
For the clinician standing at the bedside, the more useful message is simpler: when an IBD patient deteriorates, CDI should remain firmly in the differential rather than being treated as an incidental possibility.
And once CDI is identified, management should not become an either-or exercise.
The patient may have infection.
The patient may have active IBD.
Very often, the practical challenge is that both need attention at the same time.
The diagnostic problem begins before the prescription pad
One of the strongest practical messages in the update concerns testing.
Patients with IBD who develop new or worsening diarrhea should be evaluated for CDI, particularly when colonic disease is present. The same principle extends to patients with an end ileostomy or ileal pouch-anal anastomosis who develop an unexplained increase in output.
The more interesting question is not simply whether to test, but how to interpret the result.
The update favors a multistep toxin-based testing strategy rather than relying on polymerase chain reaction alone.
That distinction matters considerably in IBD.
PCR is highly capable of identifying the organism, but identification does not necessarily establish toxin-mediated disease. A patient can carry toxigenic C. difficile without CDI being the principal explanation for the current diarrhea. A positive PCR coupled with a negative toxin result may therefore represent colonization rather than clinically active infection.
This is one of those areas where laboratory terminology quickly becomes a bedside management issue.
A patient with active colitis may have diarrhea from intestinal inflammation, infection, medication effects, bile acid diarrhea, pouch-related disease, postinfectious symptoms, or overlapping functional symptoms. Anchoring on a molecular result can lead us in the wrong direction just as surely as failing to test at all.
Twenty-five years of gastroenterology does not make diarrhea diagnostically more obedient.
It merely makes one increasingly suspicious of single-test explanations.
The update also advises renewed testing when diarrhea recurs after recent treatment for CDI. This should not be interpreted as routine testing to document cure. Rather, recurrent symptoms require reassessment because recurrent CDI and recurrent IBD activity remain clinically difficult to distinguish.
Fidaxomicin moves to the front—but with an important qualifier
The headline therapeutic recommendation is likely to receive the most attention.
For an initial CDI episode in a patient with IBD, the AGA advises preferential use of fidaxomicin. Oral vancomycin remains an appropriate alternative when fidaxomicin is unavailable or its cost is prohibitive. Metronidazole should not be used for initial CDI in this setting.
There is biological logic behind the preference.
Fidaxomicin is relatively narrow spectrum, targets C. difficile, and causes less disruption to intestinal microbial diversity than broader antimicrobial approaches. The review also points toward lower recurrence rates as an important reason for favoring it over vancomycin. Retrospective IBD studies cited in the source have reported cure rates in the range of approximately 80%–90%.
Still, this is exactly where careful wording matters.
The update does not provide large IBD-specific randomized trials demonstrating that fidaxomicin is universally superior to vancomycin across every clinical scenario. Many CDI therapeutic trials have excluded patients with IBD, and the antibiotic data available specifically in this population remain limited and substantially retrospective.
So the practical conclusion is not:
“Every patient with IBD and CDI must receive fidaxomicin.”
It is closer to:
“When feasible, fidaxomicin deserves to be the preferred initial option, while oral vancomycin remains a clinically legitimate alternative when access or affordability dictates otherwise.”
That is a rather less dramatic sentence, but medicine usually improves when the adjectives are kept under control.
Availability, cost, disease severity, recurrence history, institutional pathways, and local practice will continue to influence what actually happens in clinic. The update acknowledges that reality rather than pretending it does not exist.
Severe disease is where diagnostic ambiguity becomes dangerous
The infection-versus-flare distinction becomes particularly consequential when the patient is clinically deteriorating.
The AGA advises strong consideration of hospitalization when IBD and CDI coexist with features suggesting severe colitis or systemic toxicity. Warning features include more than six bowel movements per day, severe abdominal pain, marked leukocytosis, hemodynamic instability, or other signs of sepsis.
Hospital admission in this situation is not simply about delivering antibiotics in a different building.
It allows closer observation, correction of fluid and electrolyte abnormalities, assessment of disease severity, imaging where appropriate, coordination of IBD therapy, and surgical involvement when the clinical trajectory demands it.
Importantly, the update does not suggest that every IBD patient with CDI belongs in hospital. These are danger signals that should lower the threshold for admission.
There is another limitation worth preserving. The individual clinical markers associated with medically refractory colitis and progression toward fulminant CDI have not been validated together as a single risk model specifically for IBD-associated CDI.
They are therefore useful clinical warning signs—not a validated bedside scoring system.
That distinction may seem academic until a risk score begins dictating management. Then it becomes very practical indeed.
Treat the infection, but do not forget the IBD
Perhaps the most clinically reassuring part of the update concerns immunosuppression.
When choosing therapy for IBD, the AGA states that no particular immunosuppressive class or mechanism of action has demonstrated a differential CDI risk sufficient to dictate treatment selection. Clinicians should choose the therapy most appropriate for controlling the patient's IBD.
More importantly, the presence of acute CDI should not automatically trigger withdrawal of necessary IBD therapy.
The update supports continuing required immunomodulators, biologics, or small molecules while CDI is treated. Corticosteroids may also be used when considered clinically necessary.
This deserves a careful reading.
The recommendation does not establish that immunosuppression during CDI is universally risk-free. The supporting evidence is largely retrospective, and randomized comparative trials are lacking. Rather, the update challenges the reflex assumption that every immunosuppressive therapy must be stopped simply because CDI has been identified.
That is an important distinction in practice.
If intestinal inflammation remains uncontrolled, successfully treating the infection alone may not restore the patient. Persistent symptoms after approximately 48–72 hours of CDI therapy should therefore prompt reassessment for ongoing IBD activity or another explanation, including cytomegalovirus infection where relevant.
The broader principle is familiar: treat what is actually harming the patient, rather than allowing one diagnosis to erase the other.
Recurrence changes the conversation
Recurrent CDI remains particularly troublesome in IBD because every recurrence can bring another round of antibiotics, further microbiome disruption, renewed diagnostic uncertainty, and potential destabilization of the underlying inflammatory disease.
The AGA update therefore brings microbiome-based therapy into the discussion relatively early.
For patients who experience at least one recurrence, the authors advise consideration of fecal microbiota transplantation or FDA-approved donor-derived microbiota restoration therapies.
That represents an important change in emphasis: recurrence management should not automatically mean another indefinite cycle of antibiotics without considering strategies aimed at restoring colonization resistance.
But again, enthusiasm needs boundaries.
Evidence is not uniform across microbiome-based products or across different IBD populations. Patient selection, disease phenotype, immunosuppression, product availability, local expertise, safety screening, and regulatory considerations all remain relevant.
Microbiome restoration is therefore an increasingly important recurrence-prevention strategy—not a guaranteed solution for every patient with recurrent CDI and IBD.
Where the evidence should make us confident—and where it should not
The value of this Clinical Practice Update lies partly in how well it organizes a messy clinical problem.
But several conclusions would go beyond what the evidence supports.
First, fidaxomicin should not be described as definitively superior in every patient with IBD and CDI. The preference is clinically meaningful, but IBD-specific comparative evidence remains limited and largely retrospective.
Second, PCR positivity is not synonymous with active toxin-mediated CDI. Colonization remains an important interpretive problem, which is why multistep toxin-based testing matters.
Third, continuing IBD therapy does not mean immunosuppression is automatically safe in every circumstance. It means necessary control of active inflammatory disease should not be reflexively abandoned while CDI is treated.
Fourth, microbiome-based therapy is not a guaranteed cure for recurrence. Evidence and experience vary by product and by IBD subgroup.
And finally, the document itself must be labelled correctly. This is an expert Clinical Practice Update, not a formal systematic review or a randomized comparative trial.
Those caveats are not footnotes to the message.
They are part of the message.
Clinical Takeaway
The 2026 AGA Clinical Practice Update encourages a more integrated approach to C. difficile infection in IBD.
When an IBD patient develops new or worsening diarrhea, CDI deserves active consideration, but diagnosis should rely on thoughtful interpretation rather than PCR positivity alone. A multistep toxin-based testing strategy helps separate active infection from colonization.
For an initial episode of nonfulminant CDI, fidaxomicin is preferred when feasible, while oral vancomycin remains an appropriate alternative when access or cost is limiting. Metronidazole should not be used as initial therapy in this setting.
Patients showing severe colitis or systemic toxicity warrant a low threshold for hospitalization. At the same time, clinicians should avoid reflexively withdrawing necessary IBD treatment simply because CDI has been diagnosed. Persistent symptoms despite initial CDI therapy should trigger reassessment for ongoing inflammatory disease or alternative causes.
After recurrence, microbiome-based strategies deserve consideration rather than repeatedly defaulting to antibiotic treatment alone.
Perhaps the most useful message is also the least fashionable: CDI and active IBD are not mutually exclusive diagnoses.
Treat the infection promptly. Interpret the laboratory result in its clinical context. Continue to assess the inflammatory disease. And keep the strength of the underlying evidence in view when moving from guidance to individual patient care.
That is not as tidy as an algorithm.
It is, however, much closer to the patient sitting in front of us.
Five points worth carrying into practice
Know what kind of evidence you are reading. This is an AGA Clinical Practice Update Expert Review, not an IBD-specific randomized trial or formal systematic review.
Testing strategy matters. New or worsening diarrhea in IBD should prompt evaluation for CDI, with multistep toxin-based testing helping distinguish active infection from colonization.
Fidaxomicin moves earlier. It is preferred for initial CDI when feasible, while oral vancomycin remains acceptable when cost or access is limiting. Metronidazole should not be used.
Do not reflexively stop necessary IBD therapy. Infection and intestinal inflammation may require concurrent management.
Recurrence should trigger a prevention discussion. Microbiome-based therapies are increasingly relevant after recurrent CDI, although evidence varies across products and IBD populations.
Source
Khanna S, Allegretti JR, Hashash JG, Feuerstadt P. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Inflammatory Bowel Disease: Expert Review. Gastroenterology. 2026;171(1):184–192. Published online May 15, 2026. DOI: 10.1053/j.gastro.2026.03.008.
Additional official AGA summary: 12 best practices for managing C. difficile infection in IBD. American Gastroenterological Association, June 9, 2026.
References
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.